112 related articles for article (PubMed ID: 11488762)
1. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide.
Yashi M; Muraishi O; Tokue A
BJU Int; 2001 Aug; 88(3):306-8. PubMed ID: 11488762
[No Abstract] [Full Text] [Related]
2. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide.
Yashi M; Muraishi O; Tokue A
BJU Int; 2000 Dec; 86(9):1091-2. PubMed ID: 11119109
[No Abstract] [Full Text] [Related]
3. Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases.
Yashi M; Ishikawa S; Tokue A
Urology; 2003 Jul; 62(1):198-9; author reply 199. PubMed ID: 12837468
[No Abstract] [Full Text] [Related]
4. Comparison of neurone-specific enolase and pro-gastrin releasing peptide in the prognostic evaluation of small cell lung cancer patients.
Satoh H; Kagohashi K; Kurishima K; Ishikawa H; Ohtsuka M
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):720. PubMed ID: 17100161
[No Abstract] [Full Text] [Related]
5. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
[TBL] [Abstract][Full Text] [Related]
6. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation.
Aoyagi K; Miyake Y; Urakami K; Kashiwakuma T; Hasegawa A; Kodama T; Yamaguchi K
Clin Chem; 1995 Apr; 41(4):537-43. PubMed ID: 7720242
[TBL] [Abstract][Full Text] [Related]
7. Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer.
Yamaguchi H; Soda H; Kitazaki T; Nakano H; Fujino S; Nakamura Y; Kohno S
Respirology; 2007 Jan; 12(1):137-9. PubMed ID: 17207039
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.
Korse CM; Holdenrieder S; Zhi XY; Zhang X; Qiu L; Geistanger A; Lisy MR; Wehnl B; van den Broek D; Escudero JM; Standop J; Hu M; Molina R
Clin Chim Acta; 2015 Jan; 438():388-95. PubMed ID: 25262909
[TBL] [Abstract][Full Text] [Related]
11. [Pro gastrin-releasing peptide (ProGRP)].
Ishikawa H; Saito T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():759-61. PubMed ID: 16149633
[No Abstract] [Full Text] [Related]
12. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
13. ProGRP: a new biomarker for small cell lung cancer.
Molina R; Filella X; Augé JM
Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
[TBL] [Abstract][Full Text] [Related]
14. A small cell carcinoma of the pancreas with a high level of serum ProGRP.
Matsubayashi H; Fujiwara S; Kobayashi Y; Iiri T; Mitra A; Goggins M; Hruban RH; Moriyasu F
J Clin Gastroenterol; 2004 Oct; 38(9):834-5. PubMed ID: 15365423
[No Abstract] [Full Text] [Related]
15. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
[TBL] [Abstract][Full Text] [Related]
16. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma.
Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H
Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170
[TBL] [Abstract][Full Text] [Related]
17. Determination of the small cell lung cancer associated biomarker pro-gastrin-releasing peptide (ProGRP) using LC-MS.
Winther B; Reubsaet JL
J Sep Sci; 2007 Feb; 30(2):234-40. PubMed ID: 17390617
[TBL] [Abstract][Full Text] [Related]
18. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
19. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
Miyake Y; Kodama T; Yamaguchi K
Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
[TBL] [Abstract][Full Text] [Related]
20. Progastrin-releasing peptide: stability in plasma/serum and upper reference limit.
Nordlund MS; Bjerner J; Warren DJ; Nustad K; Paus E
Tumour Biol; 2008; 29(3):204-10. PubMed ID: 18667845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
